The efficacies of six ALK inhibitors (ensartinib, lorlatinib, brigatinib, alectinib, ceritinib, and crizotinib) were compared with that of chemotherapy in the overall patients with ALK-p, ALK inhibitor-naïve advanced NSCLC and in the subgroup of patients with CNS metastases. Here, ALK is linked to non-small cell lung carcinoma.